factor VII

(redirected from Novoseven)
Also found in: Dictionary, Thesaurus, Medical.
Related to Novoseven: FEIBA, Novoeight

factor VII

[′fak·tər ′se·vən]
(biochemistry)
A procoagulant, related to prothrombin, that is involved in the formation of a prothrombin-converting principle which transforms prothrombin to thrombin. Also known as stable factor.
References in periodicals archive ?
NovoSeven was licensed in 1999 for use to stem bleeding in haemophiliacs but is still undergoing trials for use on trauma patients with severe wounds.
But the MoD said NovoSeven is used only as a last resort.
The patients in the study, which was funded by Novo Nordisk, the maker of NovoSeven, had ICH confirmed by CT within 3 hours of onset; treatment was administered within 1 hour of the baseline scan.
In addition, she received NovoSeven through intravenous infusion every 2 hours until her condition stabilized.
She has driven a broad spectrum of program management for Novo Nordisk and their brands including Novolog, FlexPen, Novoseven, Levemir and others.
Tenders are invited for Inj Factor Vial Novoseven 2 Mg 100 Kiu With Infusion Kit
Our study shows you individual revenue forecasts to 2024 for 10 marketed products, including these: -- Advate -- NovoSeven -- Kogenate -- BeneFIX -- FEIBA.
Recombinant factor VIIa (rFVIIa, NovoSeven, Novo Nordisk, Princeton, NJ) is a novel hemostatic agent, manufactured using recombinant DNA technology.
NovoSeven Coagulation Factor VIIa (Recombinant) was approved in 1999 to treat bleeding episodes in hemophilia A or B patients with clotting inhibitors to Factor VIII or Factor IX.